The keynotes speakers contributed to the iMNC 2016:
- Shane Bowen – Director of Scientific Research at Illumina
- Andrew deMello – Professor of Biochemical Engineering ETH Zurich
- Frank de Jong – Director, Research and Technology at FEI Company
- Pamela Habibovic – Professor at the MERLN Institute for Technology-Inspired Regenerative Medicine
- Andreas Hierlemann – Professor at the Department BSSE of ETH Zurich in Basel
- Oliver Paul – professor of Microsystems Engineering (IMTEK), University of Freiburg
- Peter Seeberger – Professor at the Max-Planck Institute for Colloids and Surfaces
- Ali Tinazli – Global Head of Healthcare and Life Sciences Strategy CTO Office – Strategy & Incubation, HP
Shane Bowen – Director of Scientific Research at Illumina
Illumina’s goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Illumina is a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality. Their innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.
Today, illumina is the global leader in genomics. At the foundation of illumina’s technologies lies an integrated solution that combines traditionally orthogonal scientific and engineering disciplines. Nanofabrication has been instrumental in the realization of the $1000 genome in 2014 and is enabling new solutions to build upon in the future.
Frank de Jong – Director, Research and Technology at FEI Company
Frank de Jong is world-wide Director of Research and Advanced Technology for FEI Company; a US-based company selling Tools for Nanotech, focusing on Electron Microscopy and Focused Ion-beam equipment. The European part of the company is based in Eindhoven, The Netherlands, and is a major centre for R&D.
Frank de Jong started his professional career at the Philips Research Laboratory in 1984. He graduated in Applied Physics at Delft University in 1990. In 1992 he started working for the Philips Electron Optics business group; which later merged with FEI Company. He became Director for Research and Technology in 2006; since 2011 acting in a global role.
Pamela Habibovic – Professor at the MERLN Institute for Technology-Inspired Regenerative Medicine
The main focus of her research group is on synthetic bone graft substitutes, bioinorganics and high-throughput approaches in biomaterials research.Pamela Habibović obtained her PhD degree in 2005 from the University of Twente in the Netherlands. Following two post-doctoral research projects, one at Children’s Hospital Boston-Harvard Medical School in Biston, USA and the other at McGill University in Montreal, Canada, she returned to the Netherlands, where she led a research group at the University of Twente’s MIRA Institute for Biomedical Technology and Technical Medicine between 2008 and 2014, first as assistant and later as associate professor. In 2014, she moved to Maastricht University, where she became full professor of Inorganic Biomaterials and chair of IBE.Back to the top
Andrew deMello is Professor of Biochemical Engineering in the Department of Chemistry and Applied Biosciences at ETH Zurich and Head of the Institute for Chemical and Bioengineering.
His primary specializations include the development of microfluidic devices for high-throughput biological and chemical analysis, ultra-sensitive optical detection techniques, nanofluidic reaction systems for chemical synthesis, novel methods for nanoparticle synthesis, the exploitation of semiconducting materials in diagnostic applications, the development of intelligent microfluidics and the processing of living organisms.
Andreas Hierlemann – Prof. at the Department BSSE of ETH Zurich in Basel
Andreas Hierlemann completed his college education in chemistry at the University of Tübingen, Germany, and was awarded a Ph.D. degree in 1996. He then held Postdoctoral positions at Texas A & M University, College Station, TX, USA, in 1997, and at Sandia National Laboratories, Albuquerque, NM, USA, in 1998. In 1999, he joined the Department of Physics, ETH Zurich, Switzerland, where he was appointed Associate Professor in June 2004. In April 2008, he became a Full Professor in the Department of Biosystems Science and Engineering (BSSE), ETH Zurich, Basel. His research interests include the development and application of microsensor, microfluidic, and microelectronic technologies to address questions in biology and medicine with applications in the fields of systems biology, drug testing, personalized medicine, and neuroscience.
Oliver Paul is a professor at the Department of Microsystems Engineering (IMTEK) of the University of Freiburg. He heads the Professorship for MEMS materials and is a co-director of the University of Freiburg’s cluster of excellence BrainLinks-BrainTools.
His research focuses on process technology and materials characterization for MEMS based on silicon technologies, in particular complementary metal oxide silicon (CMOS) technology, as well as silicon based MEMS devices and systems for physical measurements, automation, reliability testing and life science applications.
Peter Seeberger – Professor at the Max-Planck Institute for Colloids and Surfaces
His research focus is on elucidating the role of complex oligosaccharides involved in a host of biological processes of medical relevance by employing molecular tools created by synthetic chemistry. The research in Professor Seeberger’s laboratory has resulted in two spin-off companies: Ancora Pharmaceuticals (Medford, USA) that is currently developing carbohydrate vaccines against malaria and neglected diseases and i2chem (Cambridge, USA) that is commercializing microreactors for chemical applications.
Ali Tinazli – Global Head of Healthcare and Life Sciences Strategy CTO Office – Strategy & Incubation, HP
Dr. Ali Tinazli has a deep background in the science and business of biomedicine and healthcare. He received his PhD in BioChemistry from J.W. Goethe University in Germany, and also studied business at UC, Berkeley’s Haas School of Business and MIT’s Sloan School of Management. From 2008-2015, Dr. Tinazli, built the biomedical consumables business at Sony DADC (part of SONY Corporation). In December 2015, Ali Tinazli joined HP’s CTOs office in Palo Alto (CA) and is leading the corporate-wide, global strategy for Healthcare and Life Sciences.
In addition to his bioscience and industry domain experience, Ali brings strong entrepreneurial experience and hands-on knowledge of the biosciences start-up community. He currently sits on the Advisory Board of a bioinformatics/computer processor company, and serves as a Board Member at various start-up companies in the biomedical/digital health space